Suggested remit - To appraise the clinical and cost effectiveness of ozanimod within its marketing authorisation for treating relapsing multiple sclerosis.
Status In progress
Process STA 2018
ID number 1294

Provisional Schedule

Committee meeting: 1 13 May 2020
Expected publication 22 July 2020

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors Celgene (ozanimod)
Others Department of Health
  NHS South Eastern Hampshire CCG
  NHS Somerset CCG
  NHS England
  Welsh Government
Patient carer groups Brain Charity
  Brain and Spine Foundation
  Disability Rights UK
  Leonard Cheshire Disability
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Muslim Council of Britain
  Neurological Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Sue Ryder
Professional groups Association of British Neurologists
  Association of Neuroscience Nurses
  British Neuropathological Society
  Institute of Neurology
  Neuromodulation Society of UK and Ireland
  Primary Care Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Speech and Language Therapists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Bayer (interferon beta-1b)
  Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab, peginterferon beta-1a)
  Genzyme Therapeutics (alemtuzumab, teriflunomide)
  Merck Serono (cladribine tablets, interferon beta-1a)
  Novartis (fingolimod, interferon beta-1b)
  Teva UK (glatiramer acetate)
  Roche (ocrelizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  British Neurological Research Trust
  Cochrane Multiple Sclerosis Group
  MRC Clinical Trials Unit
  National Hospital for Neurology and Neurosurgery
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
02 September 2019 Invitation to participate
30 August 2019 In progress, In progress
30 January 2018 - 27 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance